Top Markets
Coin of the day
Myriad Genetics, Inc. Myriad Genetics, Inc.

Myriad Genetics, Inc.

MYGN
Pozycja w akcjach #16419
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company,... Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Cena akcji
$3.12
Ostatnia synchronizacja: 2026-09-01
Kapitalizacja rynkowa
$294.21M
Zmiana (1 dzień)
-3.26%
Zmiana (1 rok)
-54.86%
Kraj
US
Handel Myriad Genetics, Inc. (MYGN)

Kategoria

Liczba akcji w obrocie dla Myriad Genetics, Inc. (MYGN)
Liczba akcji w obrocie na dzień September 2026: 0
Zgodnie z najnowszymi raportami finansowymi i ceną akcji Myriad Genetics, Inc., aktualna liczba akcji w obrocie to 0. Na koniec September 2026 firma posiadała 0 akcji w obrocie. Liczba akcji w obrocie jest zwykle kształtowana przez podziały akcji i skupy akcji.
Historia liczby akcji w obrocie dla Myriad Genetics, Inc. (MYGN) od 2026 do 2026
Akcje w obrocie na koniec każdego roku
Rok Akcje w obrocie Zmień
Za mało danych dla podanych dat.
Akcje w obrocie dla podobnych firm lub konkurentów
Firma Akcje w obrocie Różnica Kraj
371.00M -
US
705.30M -
US
- -
CN
143.28M -
US
80.10M -
US